The CPIT III Trial Research Group

Smoking Cessation in Pregnancy Incentives Trial (CPIT) : A Phase III Randomised Controlled Trial (2017-2020)

This 39 month study will compare smoking cessation rates in late pregnancy and 6 months post partum between women offered routine NHS stop smoking support and those offered the same NHS support plus additional financial incentives.  The aim is to show that within a range of usual care situations, the addition of incentives increases smoking cessation; that stopping during pregnancy leads to prolonged cessation to at least six months after birth, and that the addition of incentives is cost effective and well below the threshold set by NICE to recommend widespread deployment of a new intervention.



Research Group Lead

Professor David Tappin

Prof David M Tappin leads the CPIT III trial group, performing evaluation of specialist smoking cessation services for pregnant women throughout Scotland.   This group looks at accuracy of self reporting by pregnant smokers, seeking to improve treatment of smoking during pregnancy in Scotland by establishing methods to identify all smokers, improving methods of referral and engagement and treatment including access to nicotine replacement therapy.

Research Contacts

Margaret McFadden

Margaret is a Senior Research Nurse at NHS Glasgow Clinical Research Facility.  She has extensive experience in a variety of clinical areas and was Lead Trial Nurse for the CPIT (Cessation in Pregnancy Incentives Trial) Pilot Study from 2012 - 2014.   Following the completion of her MSc, she has worked as lead nurse in complex CTIMPs (Clinical Trials of Investigational Medicinal Products) Phase 1 - IV, and is relishing the opportunity to re-join the CPIT team for this multicentre trial.

Lesley Sinclair

Lesley Sinclair is the CPIT III trial manager, whose expertise is in conducting health services research including randomised controlled trials.  From 2012-2014, Lesley was the trial manager for the first CPIT (Cessation in Pregnancy Incentives Trial), the world's largest trial to date of financial incentives for smoking cessation.